RU2336871C2 - Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора - Google Patents

Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора Download PDF

Info

Publication number
RU2336871C2
RU2336871C2 RU2004137091/15A RU2004137091A RU2336871C2 RU 2336871 C2 RU2336871 C2 RU 2336871C2 RU 2004137091/15 A RU2004137091/15 A RU 2004137091/15A RU 2004137091 A RU2004137091 A RU 2004137091A RU 2336871 C2 RU2336871 C2 RU 2336871C2
Authority
RU
Russia
Prior art keywords
colon
compounds
effective
pain
asimadoline
Prior art date
Application number
RU2004137091/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004137091A (ru
Inventor
Франк ВЕБЕР (DE)
Франк ВЕБЕР
Ютта ЯКОБ (DE)
Ютта ЯКОБ
Эндрью БАРБЕР (DE)
Эндрью БАРБЕР
Рудольф ГОТТШЛИХ (DE)
Рудольф ГОТТШЛИХ
Original Assignee
Тиога Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиога Фармасьютиклз, Инк. filed Critical Тиога Фармасьютиклз, Инк.
Publication of RU2004137091A publication Critical patent/RU2004137091A/ru
Application granted granted Critical
Publication of RU2336871C2 publication Critical patent/RU2336871C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2004137091/15A 2002-05-17 2003-04-28 Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора RU2336871C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011047 2002-05-17
EP02011047.4 2002-05-17

Publications (2)

Publication Number Publication Date
RU2004137091A RU2004137091A (ru) 2005-09-10
RU2336871C2 true RU2336871C2 (ru) 2008-10-27

Family

ID=29433078

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004137091/15A RU2336871C2 (ru) 2002-05-17 2003-04-28 Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора

Country Status (20)

Country Link
US (1) US20050176746A1 (https=)
EP (2) EP1505974B1 (https=)
JP (1) JP2005531557A (https=)
KR (1) KR101108014B1 (https=)
CN (2) CN101310723A (https=)
AR (1) AR040028A1 (https=)
AT (1) ATE429226T1 (https=)
AU (1) AU2003242527B2 (https=)
BR (1) BR0309969A (https=)
CA (1) CA2486000A1 (https=)
DE (1) DE60327315D1 (https=)
DK (1) DK1505974T3 (https=)
ES (1) ES2325782T3 (https=)
MX (1) MXPA04011333A (https=)
PE (1) PE20040455A1 (https=)
PL (1) PL371596A1 (https=)
RU (1) RU2336871C2 (https=)
TW (1) TWI314053B (https=)
WO (1) WO2003097051A2 (https=)
ZA (1) ZA200410160B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023231B1 (ru) * 2013-07-18 2016-05-31 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
RU2413512C1 (ru) * 2009-07-29 2011-03-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" Средство, обладающее каппа-опиоидной агонистической активностью
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
US20160250277A1 (en) * 2013-10-28 2016-09-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
RU96112771A (ru) * 1995-06-28 1998-09-27 Мерк Патент Гмбх Соединения с проконвертин-опиатагонистической активностью, содержащие их композиции, способ их получения, способ лечения
WO2001098276A1 (de) * 2000-06-23 2001-12-27 Henkel Kommanditgesellschaft Auf Aktien Paraaminophenol-derivate und deren verwendung als entwickler zur erzeugung von oxidationsfarbungen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4215231C1 (en) 1992-05-09 1993-05-13 Dornier Luftfahrt Gmbh, 8031 Wessling, De Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
JPH11343244A (ja) * 1998-03-30 1999-12-14 Taisho Pharmaceut Co Ltd 経口用組成物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
WO2000004050A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
WO2001097753A2 (en) * 2000-06-19 2001-12-27 Eisai Co. Ltd. Novel methods using pyridine derivatives
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US6780891B2 (en) * 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
RU96112771A (ru) * 1995-06-28 1998-09-27 Мерк Патент Гмбх Соединения с проконвертин-опиатагонистической активностью, содержащие их композиции, способ их получения, способ лечения
WO2001098276A1 (de) * 2000-06-23 2001-12-27 Henkel Kommanditgesellschaft Auf Aktien Paraaminophenol-derivate und deren verwendung als entwickler zur erzeugung von oxidationsfarbungen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mendelson SD. Treatment of anorexia nervosa with tramadol. Am J Psychiatry. 2001 Jun; 158(6): 963-4. Двадцать пять наиболее перспективных разработок фармацевтических компаний, [on line] Фарматека №3 (99) [найдено 27.03.2007]. Найдено из Интернет: <yandex:http://www.pharmateca.ru/cgi-. bin/statyi.p1?sid=669&mid=1085056555&magid=55&full=1/. реферат Entrez PubMed: Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol. 1999 Mar; 13 Suppl A: 71A-75A. [on line] PMID: 10202212 [найдено 27.03.2007]. реферат Entrez PubMed: Delvaux M. Pharmacology and clinical experience with fedotozine. Expert Opin Investig Drugs. 2001 Jan; 10(1):97-110 [on line] PMID: 11116283 [найдено 27.03.2007]. реферат Entrez PubMed: De Winter BY et al. Effects of mu- and kappa-opioid receptors on postoperative ileus in rats. Eur J Pharmacol. 1997 Nov 19; 339(1): 63-7 [on line] PMID: 9450617 [найдено 27.03.2007]. *
WO 02/13801 A2 (CPD, LLC), 21.02.2002. реферат Entrez PubMed: Gevaerd MS. et al. Combined effects of diethylpropion and alcohol on locomotor activity of mice: participation of the dopaminergic and opioid systems. Braz J Med Biol Res. 1999 Dec; 32(12): 1545-50. [on line] PMID: 10585638 [найдено 30.03.2007]. ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ М., РЛС 2001 с.1067-1068, 583-585 М.Д.МАШКОВСКИЙ Лекарственные средства М., 2001 ч.1 с.123 реферат Entrez PubMed: Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch INTERN Med. 2001 Aug 13-27. 161(15): 1814-24 [on line] PMID: 11493122 [найдено 30.03.2007]. *
реферат Entrez PubMed: Jarosz PA. et al. The effect of opioid antagonism on food intake behavior and body weight in a biobehavioral model of obese binge eating. Biol Res Nurs. 2002 Apr; 3(4): 198-209. [on line] PMID: 12184663 [найдено 27.03.2007]. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023231B1 (ru) * 2013-07-18 2016-05-31 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина

Also Published As

Publication number Publication date
DE60327315D1 (de) 2009-06-04
DK1505974T3 (da) 2009-08-17
KR20050010807A (ko) 2005-01-28
TWI314053B (en) 2009-09-01
AR040028A1 (es) 2005-03-09
ES2325782T3 (es) 2009-09-17
ZA200410160B (en) 2005-12-28
US20050176746A1 (en) 2005-08-11
AU2003242527A1 (en) 2003-12-02
EP1505974A2 (en) 2005-02-16
HK1079451A1 (zh) 2006-04-07
CN100411618C (zh) 2008-08-20
KR101108014B1 (ko) 2012-01-25
BR0309969A (pt) 2005-04-26
TW200307541A (en) 2003-12-16
WO2003097051A3 (en) 2004-12-09
ATE429226T1 (de) 2009-05-15
PL371596A1 (en) 2005-06-27
MXPA04011333A (es) 2005-02-14
AU2003242527B2 (en) 2008-10-23
RU2004137091A (ru) 2005-09-10
WO2003097051A2 (en) 2003-11-27
CA2486000A1 (en) 2003-11-27
CN1655784A (zh) 2005-08-17
PE20040455A1 (es) 2004-08-07
CN101310723A (zh) 2008-11-26
EP2074997A1 (en) 2009-07-01
JP2005531557A (ja) 2005-10-20
EP1505974B1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
RU2336871C2 (ru) Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора
JP2584899B2 (ja) 体重減量医薬組成物
RU2522212C2 (ru) Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
US20210186990A1 (en) Methods and compositions for treating various disorders
PL185528B1 (pl) Kompozycja farmaceutyczna do modulowania przepływu krwi do genitaliów i zastosowanie fentolaminy do wytwarzania leku do leczenia impotencji
ES2762113T3 (es) Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
BR112013015957B1 (pt) Uso de naltrexona ou um sal farmaceuticamenteaceitável da mesma e bupropiona ou um salfarmaceuticamente aceitável da mesma, composiçãofarmacêutica e kit
KR20150120479A (ko) 니트라이트의 약제학적 제형 및 이의 용도
WO2006022420A1 (ja) 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2017048457A1 (en) Combination of laquinimod and pridopidine to treat multiple sclerosis
US20240197756A1 (en) Methods of treatment with neuroactive steroids
WO2016167855A1 (en) Combination of albuterol and caffeine as synergistic treatment for obesity or sarcopenia
TW201841903A (zh) 末梢神經障礙之治療劑或預防劑
HK1079451B (en) Use of compounds that are effective as selective opiate receptor modulators
AU2015360620A1 (en) Treatment of multiple sclerosis with combination of laquinimod and a statin
Butsch et al. Medical Treatment of Obesity
WO2024054412A1 (en) Methods and compositions for treating amyotrophic lateral sclerosis
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
JP2020172475A (ja) メロキシカム又はその薬学的に許容される塩を含有する内服治療剤
JP2008273859A (ja) 腎機能障害を持つ心不全患者を治療するためのコハク酸シベンゾリンを有効成分とする不整脈治療剤
EVANS Depression, Anxiety Erode Cardiac Rehab Progress
WO2004110429A1 (en) Use of substituted chromans or thiocromans for the treatment of ibs
Tablets et al. RAN-Pioglitazone
NZ614725A (en) Methods and compositions for treating depression using cyclobenzaprine
NZ614725B2 (en) Methods and compositions for treating depression using cyclobenzaprine

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140429